Fluorine in Drug Design: A Case Study with Fluoroanisoles

Xing Li(Pfizer (United States)), David C. Blakemore(Pfizer (United Kingdom)), Arjun Narayanan(Pfizer (United States)), Ray Unwalla(Pfizer (United States)), Frank Lovering(Pfizer (United States)), R. Aldrin Denny(Pfizer (United States)), Huanyu Zhou(Pfizer (United States)), Mark E. Bunnage(Pfizer (United States))
ChemMedChem
March 6, 2015
Cited by 150

Abstract

Anisole and fluoroanisoles display distinct conformational preferences, as evident from a survey of their crystal structures. In addition to altering the free ligand conformation, various degrees of fluorination have a strong impact on physicochemical and pharmacokinetic properties. Analysis of anisole and fluoroanisole matched molecular pairs in the Pfizer corporate database reveals interesting trends: 1) PhOCF3 increases log D by ~1 log unit over PhOCH3 compounds; 2) PhOCF3 shows lower passive permeability despite its higher lipophilicity; and 3) PhOCF3 does not appreciably improve metabolic stability over PhOCH3 . Emerging from the investigation, difluoroanisole (PhOCF2 H) strikes a better balance of properties with noticeable advantages of log D and transcellular permeability over PhOCF3 . Synthetic assessment illustrates that the routes to access difluoroanisoles are often more straightforward than those for trifluoroanisoles. Whereas replacing PhOCH3 with PhOCF3 is a common tactic to optimize ADME properties, our analysis suggests PhOCF2 H may be a more attractive alternative, and greater exploitation of this motif is recommended.


Related Papers

No related papers found

Powered by citation graph analysis